Thailand Oncology Drugs Market Report 2022 to 2030

Thailand Oncology Drugs Market Analysis

$ 3999

By 2030, it is anticipated that the Thailand oncology drugs market will reach a value of $xx Mn from $xx Mn in 2022, growing at a CAGR of xx% during 2022-30. The oncology drugs market in Thailand is dominated by a few domestic pharmaceutical companies such as Siam Bioscience, GPO, and Mega Lifesciences. The oncology market in Thailand is segmented into different therapeutic areas and different treatment types. The major factors affecting the Thailand oncology drugs market are the increasing disease burden of non-communicable diseases like cancer and the lack of healthcare facilities for cancer treatment in most areas of Thailand.

ID: IN10THPH018 CATEGORY: Pharmaceuticals GEOGRAPHY: Thailand AUTHOR: Dr. Vishwa Modhia

Buy Now

Thailand Oncology Drugs Market Analysis Summary

By 2030, it is anticipated that the Thailand oncology drugs market will reach a value of $xx Mn from $xx Mn in 2022, growing at a CAGR of xx% during 2022-30.

Thailand is an upper middle-income, developing country located in Southeastern Asia bordering the Andaman Sea and the Gulf of Thailand. The National Cancer Institute of Thailand offers financial assistance for specific cancer treatments, such as chemotherapy and targeted therapies. The Thai Red Cross Society also provides financial support to cancer patients who require expensive therapies.

Thailand has an increasing number of cancer treatment facilities, including state hospitals and private clinics. This allows more patients to receive cancer therapies, such as oncology medications. Thailand's government spends 4.4 % of its GDP on healthcare.

Market Dynamics

Market Growth Drivers Analysis

The Thai government has established the National Cancer Institute of Thailand and the Universal Health Coverage Scheme to improve cancer care in the country. These projects aim to raise cancer awareness, prevention, treatment, and patient support. Thailand is a regional hub, with lengthy coasts and close proximity to rapidly expanding Asian markets. These aspects could boost Thailand's oncology drugs market.

Market Restraints

Oncology drugs are usually expensive, making them inaccessible to many Thai patients. Thailand's healthcare system is not as developed as in some other nations, which can hinder pharmaceutical companies' capacity to contact patients and market their goods. Oncology drug market rivalry is often fierce, both from other pharmaceutical companies and from other treatment options such as radiation therapy and surgery. Companies may find it challenging to obtain market share and generate significant commercial growth as a result of this. Thailand has an uncertain political environment and animosity between rural and urban communities. These factors may deter new entrants into the Thailand oncology drugs market.

Competitive Landscape

Key Players

Siam Bioscience (THA)
Mega Lifesciences (THA)
Siam Pharmaceutical (THA)
GPO (Government Pharmaceutical Organization) (THA)
Hoffmann-La Roche Ltd
Novartis AG
Gilead Sciences Inc
Bayer AG

Recent Notable Updates

September 2020: PTT Plc, Thailand's national oil and gas giant, has teamed with the Government Pharmaceutical Organization (GPO) to build Thailand's first cancer pharmaceutical facility at a cost of $70 Mn. The two-state enterprises inked a collaborative development agreement for the factory Wednesday in Bangkok, with the goal of cutting cancer medical bills by half. The factory will be built in PTT We Cozi, PTT's flagship industrial area in Rayong, with the first dosages expected to be distributed in 2027.

Healthcare Policies and Reimbursement Scenarios

The Food and Drug Administration regulates oncology medications in Thailand (FDA). The FDA guarantees that oncology drugs are safe, effective, and of high quality before they are placed on the Thai market. Before an anticancer medicine may be used in Thailand, it must first go through clinical studies to demonstrate its safety and efficacy. Before oncology medications can be marketed and sold in Thailand, they must be registered with the FDA.

The Thai government offers the Universal Coverage Scheme (UCS), a national health insurance policy that covers hospitalization, outpatient care, laboratory tests, and medicines, including oncology therapies. The UCS includes chemotherapy, targeted medicines, and radiation therapy among other cancer treatments. The program also includes supportive treatment for people with advanced cancer, such as pain management and palliative care. Other government programs, in addition to the UCS, provide financial aid for oncology medications.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Oncology Drugs Market Segmentation

By Drug class

Cytotoxic drugs
- Alkylating agents
- Antimetabolites
- Others
Targeted drugs
- Monoclonal antibodies
- Others
Hormonal drugs
Others

By Therapy

Chemotherapy
Targeted therapy
Immunotherapy

By Indication

Lung cancer
Stomach cancer
Colorectal cancer
Breast cancer
Prostate cancer
Others

By Dosage form

Solid
- Tablets
- Capsules
Liquid
Injectable
- Prefilled syringes
- Others

By Distribution channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.